Moderna will pay up to $2.25B to end COVID vaccine patent fight [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on March 3. Under the deal, Moderna will pay $950 million upfront in July 2026, with an additional $1.3 billion that depends on the outcome of a separate legal appeal. The deal resolves all U.S. and international legal actions accusing Moderna of using lipid nanoparticle, or LNP, a delivery technology owned by Genevant and Arbutus, without permission in its COVID vaccine. Moderna said in a press release that it would not owe the companies any royalties for LNP technology in its future vaccines under the agreement. Lipid nanoparticles act as a tiny protective shell that helps fragile mRNA molecules reach human cells intact, allowing the vaccine to work as intended. Moderna shares jumped more than 10% in after-hours trading
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge [Yahoo! Finance]Yahoo! Finance
- Pfizer: Obesity Hype And Vaccine Policy Shocks [Seeking Alpha]Seeking Alpha
- Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline [Yahoo! Finance]Yahoo! Finance
- Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight [Yahoo! Finance]Yahoo! Finance
- ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/3/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- PFE's page on the SEC website